Overview
- Repertoire receives $85 million upfront and is eligible for up to about $1.84 billion in development and commercial milestones plus tiered royalties.
- Repertoire will use its Decode T‑cell discovery platform to generate up to three autoimmune drug candidates before handing programs to Lilly.
- Under the agreement, Lilly will lead clinical development, manufacturing, regulatory work and commercialization.
- The companies have not disclosed which autoimmune diseases they plan to target, and they aim for approaches that avoid broad immune suppression.
- The deal extends Repertoire’s partnership‑first strategy and comes as Lilly builds out immunology following moves such as the 2024 Morphic acquisition.